EPIX ESSA Pharma Inc. revenue, earnings and financials
For the quarter ended June 30, 2025, ESSA Pharma Inc. reported revenue of n/a, net income of −$4.00M and diluted EPS of −$0.09; for the fiscal year ended September 2024 revenue was n/a.
EPIX annual revenue and earnings
- Fiscal year ended Sep 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$28.5M (margin n/a), EPS −$0.64
- Fiscal year ended Sep 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$26.6M (margin n/a), EPS −$0.60
- Fiscal year ended Sep 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$35.1M (margin n/a), EPS −$0.80
- Fiscal year ended Sep 2021: revenue n/a, gross profit n/a, operating income n/a, net income −$36.8M (margin n/a), EPS −$0.96
EPIX quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income −$4.00M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.37M, EPS −$0.14
- Quarter ended Dec 31, 2024: revenue n/a, net income −$8.53M, EPS n/a
- Quarter ended Sep 30, 2024 (from the annual report): revenue n/a, net income −$6.36M, EPS −$0.14
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.23M, EPS −$0.16
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.99M, EPS −$0.20
- Quarter ended Dec 31, 2023: revenue n/a, net income −$5.96M, EPS −$0.14
- Quarter ended Sep 30, 2023 (from the annual report): revenue n/a, net income −$5.48M, EPS −$0.12
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.30M, EPS −$0.17
- Quarter ended Mar 31, 2023: revenue n/a, net income −$7.06M, EPS −$0.16
- Quarter ended Dec 31, 2022: revenue n/a, net income −$6.74M, EPS −$0.15
- Quarter ended Sep 30, 2022 (from the annual report): revenue n/a, net income −$6.32M, EPS −$0.14
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.83M, EPS −$0.20
- Quarter ended Mar 31, 2022: revenue n/a, net income −$10.9M, EPS −$0.25
- Quarter ended Dec 31, 2021: revenue n/a, net income −$9.10M, EPS −$0.21
- Quarter ended Jun 30, 2021: revenue n/a, net income −$8.75M, EPS −$0.21
- Quarter ended Mar 31, 2021: revenue n/a, net income −$13.0M, EPS −$0.36
EPIX cash flow, buybacks and dividends
- Fiscal year ended Sep 2024: operating cash flow −$22.7M, share buybacks n/a
- Fiscal year ended Sep 2023: operating cash flow −$19.8M, share buybacks n/a
- Fiscal year ended Sep 2022: operating cash flow −$28.0M, share buybacks n/a
- Fiscal year ended Sep 2021: operating cash flow −$25.4M, share buybacks n/a
EPIX balance sheet
- Jun 30, 2025: cash $86.0M, total assets $111M, total liabilities $1.60M, shareholders' equity $109M
- Mar 31, 2025: cash $86.3M, total assets $115M, total liabilities $1.87M, shareholders' equity $114M
- Dec 31, 2024: cash $93.3M, total assets $123M, total liabilities $3.87M, shareholders' equity $119M
- Sep 30, 2024: cash $104M, total assets $128M, total liabilities $3.51M, shareholders' equity $125M
- Jun 30, 2024: cash $86.0M, total assets $133M, total liabilities $3.80M, shareholders' equity $129M
- Mar 31, 2024: cash $91.7M, total assets $138M, total liabilities $4.43M, shareholders' equity $133M
- Dec 31, 2023: cash $35.3M, total assets $144M, total liabilities $3.81M, shareholders' equity $141M
- Sep 30, 2023: cash $33.7M, total assets $149M, total liabilities $3.50M, shareholders' equity $146M
Is EPIX profitable?
No. ESSA Pharma Inc. lost $25.3M over the last four quarters.